Pharsight

1. List of Braftovi drug patents

Patent Number	Company	Patent Title	Patent Expiry
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US8946250	ARRAY BIOPHARMA INC	3,4-diarylpyrazoles as protein kinase inhibitors	Jul, 2029 (6 years from now)
US8541575	ARRAY BIOPHARMA INC	3,4-diarylpyrazoles as protein kinase inhibitors	Feb, 2030 (6 years from now)
US8501758	ARRAY BIOPHARMA INC	Compounds and compositions as protein kinase inhibitors	Aug, 2030 (7 years from now)
US9593099	ARRAY BIOPHARMA INC	Compounds and compositions as protein kinase inhibitors	Aug, 2030 (7 years from now)
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9850230	ARRAY BIOPHARMA INC	Compounds and compositions as protein kinase inhibitors	Aug, 2030 (7 years from now)
US9850229	ARRAY BIOPHARMA INC	Compounds and compositions as protein kinase inhibitors	Aug, 2030 (7 years from now)
US9593100	ARRAY BIOPHARMA INC	Compounds and compositions as protein kinase inhibitors	Aug, 2030 (7 years from now)
US10005761	ARRAY BIOPHARMA INC	Compounds and compositions as protein kinase inhibitors	Aug, 2030 (7 years from now)
US9314464	ARRAY BIOPHARMA INC	Compounds and compositions as protein kinase inhibitors	Jul, 2031 (8 years from now)
US10258622	ARRAY BIOPHARMA INC	Method of treating colorectal cancer by administration of pharmaceutical formulations of (S)-methyl (1-((4-(3-(5-chloro-2-fluoro-3-(methylsulfonamido)pheny1)-1-isopropyl-1H-pyrazol-4-yl)pyrimidin-2-yl)amino)propan-2-yl) carbamate	Nov, 2032 (9 years from now)
US9387208	ARRAY BIOPHARMA INC	Pharmaceutical formulations of (S)-methyl (1-((4-(3-(5-chloro-2-fluoro-3-(methylsulfonamido)phenyl)-1-isopropyl-1H-pyrazol-4-yl)pyrimidin-2-yl)amino)propan-2-yl)carbamate	Nov, 2032 (9 years from now)
US9763941	ARRAY BIOPHARMA INC	Method of treating melanoma by administration of pharmaceutical formulations of (S)-methyl (1-((4-(3-(5-chloro-2-fluoro-3-(methylsulfonamido)phenyl)-1-isopropyl-1H-pyrazol-4-yl)pyrimidin-2-yl)amino)propan-2-yl)carbamate	Nov, 2032 (9 years from now)
US9474754	ARRAY BIOPHARMA INC	Pharmaceutical combinations comprising a B-RAF inhibitor, and EGFR inhibitor and optionally a PI3K-α inhibitor	Aug, 2033 (10 years from now)

Exclusivity	Exclusivity Expiration
New Chemical Entity Exclusivity (NCE)	Jun 27, 2023
Orphan Drug Exclusivity (ODE)	Jun 27, 2025
New Indication (I)	Apr 8, 2023

NCE-1 date: 2022-06-27

Market Authorisation Date: 27 June, 2018

Treatment: Treatment of melanoma with a braf mutation; Braftovi is a kinase inhibitor indicated in combination with cetuximab, for the treatment of adult patients with metastatic colorectal cancer (crc) with a b...

Dosage: CAPSULE;ORAL